Prix bas
CHF177.60
Habituellement expédié sous 4 à 9 semaines.
This ambitious reference surveys worldwide efforts at controlling the spread of tuberculosis, with special emphasis on the developing world. Case studies from China, Pakistan, Nigeria, Indonesia, and other frontline countries demonstrate a wealth of information on clinical, cultural, socioeconomic, and other relevant factors. This compilation provides a valuable resource for creating successful intervention and prevention strategies. State-of-the-science snapshots pinpoint where short- and long-term initiatives stand today, from early detection and vaccination programs to new genetic technologies and drug therapies. This diverse group of perspectives and approaches offers innovative paths toward control and realistic odds for containing the threat, especially in the face of current co-epidemics and new drug-resistant strains.Among the topics in the Handbook:Diagnosis of tuberculosis: current pipeline, unmet needs, and new developmentsConcurrence of tuberculosis and other major diseasesThe tuberculosis outbreak response, investigation, and controlThe promise of new TB vaccinesDNA fingerprinting of Mycobacterium tuberculosis: a rich source of fundamental and daily applicable knowledgeGlobal tuberculosis surveillanceThe Handbook of Global Tuberculosis Control is urgent reading for leadership and staff of non-governmental organizations, government agencies, academic institutions, research centers, hospitals, and potentially businesses with interests in tuberculosis control. Additionally, the book's focus on TB in developing countries will attract a wider audience of practitioners, particularly those working in the broader fields of global public health, epidemiology, international development, and the socioeconomics of infectious diseases.
Focuses on developing countries in Asia and Africa, compared with representative countries from other regions throughout the world
Presents case studies and "snapshots" designed for public health practitioners working in global TB control
Global tuberculosis surveillance
Auteur
Yichen Lu, President, Haikou VTI Biological Institute
Hongjin Duanmu, President of Chinese National Tuberculosis Control and Prevention Society, Beijing Tuberculosis and Thoracic Tumor Research Institute
Lixia Wang, Director of National Center for TB Control and Prevention, Chinese National Center for Disease Control and Prevention
Chris Chanyasulkit, Director of TB Research Program, Haikou VTI Biological Institute
Contenu
Part I : Global TB SNAPSHOTS
China (Asia: Category 3)
India (Asia: Category 4, also including Pakistan, Afghanistan, all SE Asia except Cambodia and Burma)
Cambodia (Asia: Category 5, also including Burma, North Korea)
Algeria (Africa: Category 3)
Tanzania (Africa: Category 4, also including Angola, Sudan, Chad)
South Africa (Africa: Category 5, also including all sub-Sahara Africa except Tanzania and Angola)
Mexico (North America: Category 1, also including US and Canada)
Brazil (America: Category 2)
Honduras (America: Category 3)
Peru (America: Category 4)
Iran (Mideast: Category 1)
Turkey (Europe: Category 2)
Russia East Europe: Category 4)
USA
Botswana Africa 5)
Cuba (America 1)
Hong Kong (Asia 3)
Indonesia (Asia 4)
Nigeria (Africa 5)
Philippines (Asia 4)
Senegal Africa 4
Syria Mideast 1
Part II : Diagnosis, Treatment, and Treatment Management
Clinical diagnosis of TB: history, current practices, usefulness, defectiveness, and urgent need for new tools
A case study: an historic review of DOT in China and future projections
Drug resistant TB; various causes of treatment failures, identification of drug resistant TB, prognosis and care for drug resistant TB patients, spread and increase of drug resistant TB, threats of drug resistant TB epidemics, future worst and best case scenarios, and the urgent need for new treatment medicines.
A case study: dealing with multiple drug resistant TB in China: current practices and future management strategies
Treating TB with HIV co-infections and other immune deficiency diseases: difficulties in detecting TB in HIV infected populations, increasing treatment problems associated with ARV treatment with TB co-infections, active TB resulting from organ transplant and other immune suppression, and etc.
New TB treatment medicine research and development
A case study: the history and future projection of clinical comparative testing of various TB medical treatment options in China
Part III: Prevention
BCG immunization: historical efficacy studies, current global usage of BCG immunization, current immunization coverage, estimated efficacies in different developing countries, the risk and benefit analysis of not using BCG as a vaccine in the US and other developed countries, future perspectives, and the urgent need for more effective vaccines
A case study: retrospective efficacy evaluation of BCG immunization (comparing TB incidences between comparable populations who received the vaccine and who missed vaccination)
Latent infections: latent versus active TB, current inability for early detection, risk factors of activating latent infections, examples of local and regional outbreaks, geographic distribution of global latent infections, potential impact on TB control management, and future projections.
A case study: Beijing-strategic plan and implementation of prophylactic usage of TB treatment
New TB Vaccine research and development
Part IV: Surveillance
Global TB surveillance system:
Methodology of estimation of TB incidence and mortality
TB Socioeconomics: poverty, migration, society changes
Molecular epidemiology
A Case study: Korea: Implementation of nationwide TB epidemiology survey .
A Case study : China Web-based TB reporting system
A Case study: Japan (same content as in China for direct comparisons)